Literature DB >> 22052055

A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy.

Khalil El Karoui1, Gary S Hill, Alexandre Karras, Christian Jacquot, Luc Moulonguet, Olivier Kourilsky, Véronique Frémeaux-Bacchi, Michel Delahousse, Jean-Paul Duong Van Huyen, Alexandre Loupy, Patrick Bruneval, Dominique Nochy.   

Abstract

Thrombotic microangiopathy (TMA) occurs in IgA nephropathy, but its clinical significance is not well described. We retrospectively examined a series of 128 patients diagnosed with IgA nephropathy between 2002 and 2008 who had a mean follow-up of 44±27 months. In our series, 53% presented with lesions of TMA, acute or organized, in arteries and/or arterioles. Among patients with TMA, 4% were normotensive, 25% had controlled hypertension, and 71% had uncontrolled hypertension. Of those with uncontrolled hypertension, 26% had malignant hypertension. Histologically, the group with TMA had a significantly greater percentage of sclerotic glomeruli and worse tubulointerstitial fibrosis than those of the group without TMA. However, a significant minority of patients had near-normal histology, with minimal tubular atrophy (20%) and/or <20% interstitial fibrosis (24%). TMA rarely occurred in the absence of significant proteinuria. During follow-up, a doubling of serum creatinine or ESRD occurred in all patients with laboratory evidence of TMA, in 42% of those with morphologic evidence but no laboratory evidence of TMA, and in 11% of those without TMA. In summary, lesions of TMA are frequent in IgA nephropathy and may occur in normotensive patients with near-normal renal histology. Although the pathophysiologic mechanisms involved remain undetermined, the current study rules out severe hypertension or advanced renal disease as sole causes.

Entities:  

Mesh:

Year:  2011        PMID: 22052055      PMCID: PMC3269921          DOI: 10.1681/ASN.2010111130

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  34 in total

Review 1.  Thrombotic microangiopathies: renal and extrarenal lesions.

Authors:  D Droz; D Nochy; L H Noël; D Heudes; B Nabarra; G S Hill
Journal:  Adv Nephrol Necker Hosp       Date:  2000

2.  Primary antiphospholipid antibody syndrome and mesangial IgA glomerulonephritis.

Authors:  R Sinniah; H C Gan; K H Yoon
Journal:  Am J Nephrol       Date:  2001 Mar-Apr       Impact factor: 3.754

3.  Aberrantly glycosylated IgA molecules downregulate the synthesis and secretion of vascular endothelial growth factor in human mesangial cells.

Authors:  A Amore; G Conti; P Cirina; L Peruzzi; M Alpa; F Bussolino; R Coppo
Journal:  Am J Kidney Dis       Date:  2000-12       Impact factor: 8.860

Review 4.  Atypical hemolytic-uremic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

5.  Tubular lesions determine prognosis of IgA nephropathy.

Authors:  L Daniel; Y Saingra; R Giorgi; C Bouvier; J F Pellissier; Y Berland
Journal:  Am J Kidney Dis       Date:  2000-01       Impact factor: 8.860

Review 6.  Hypertensive emergencies.

Authors:  C J Vaughan; N Delanty
Journal:  Lancet       Date:  2000-07-29       Impact factor: 79.321

7.  Renal involvement in Castleman disease.

Authors:  Khalil El Karoui; Vincent Vuiblet; Daniel Dion; Hassan Izzedine; Joelle Guitard; Luc Frimat; Michel Delahousse; Philippe Remy; Jean-Jacques Boffa; Evangéline Pillebout; Lionel Galicier; Laure-Hélène Noël; Eric Daugas
Journal:  Nephrol Dial Transplant       Date:  2010-07-23       Impact factor: 5.992

8.  Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. I. Immunohistochemical studies.

Authors:  Gary S Hill; Khalil El Karoui; Alexandre Karras; Chantal Mandet; Jean-Paul Duong Van Huyen; Dominique Nochy; Patrick Bruneval
Journal:  Kidney Int       Date:  2010-12-15       Impact factor: 10.612

9.  The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility.

Authors:  Ian S D Roberts; H Terence Cook; Stéphan Troyanov; Charles E Alpers; Alessandro Amore; Jonathan Barratt; Francois Berthoux; Stephen Bonsib; Jan A Bruijn; Daniel C Cattran; Rosanna Coppo; Vivette D'Agati; Giuseppe D'Amico; Steven Emancipator; Francesco Emma; John Feehally; Franco Ferrario; Fernando C Fervenza; Sandrine Florquin; Agnes Fogo; Colin C Geddes; Hermann-Josef Groene; Mark Haas; Andrew M Herzenberg; Prue A Hill; Ronald J Hogg; Stephen I Hsu; J Charles Jennette; Kensuke Joh; Bruce A Julian; Tetsuya Kawamura; Fernand M Lai; Lei-Shi Li; Philip K T Li; Zhi-Hong Liu; Bruce Mackinnon; Sergio Mezzano; F Paolo Schena; Yasuhiko Tomino; Patrick D Walker; Haiyan Wang; Jan J Weening; Nori Yoshikawa; Hong Zhang
Journal:  Kidney Int       Date:  2009-07-01       Impact factor: 10.612

10.  Immunohistochemical detection of intravascular platelet microthrombi in patients with lupus nephritis and anti-phospholipid antibodies.

Authors:  María Galindo; Elena Gonzalo; María P Martinez-Vidal; Santiago Montes; Natalia Redondo; Begoña Santiago; Estibaliz Loza; José L Pablos
Journal:  Rheumatology (Oxford)       Date:  2009-06-19       Impact factor: 7.580

View more
  40 in total

1.  Membrano-proliferative glomerulonephritis, atypical hemolytic uremic syndrome, and a new complement factor H mutation: report of a case.

Authors:  Elisa Gnappi; Marco Allinovi; Augusto Vaglio; Elena Bresin; Annalisa Sorosina; Francesco P Pilato; Landino Allegri; Lucio Manenti
Journal:  Pediatr Nephrol       Date:  2012-06-05       Impact factor: 3.714

2.  Renal thrombotic microangiopathy associated to worse renal prognosis in Lupus Nephritis.

Authors:  Fernando Louzada Strufaldi; Precil Diego Miranda de Menezes Menezes Neves; Cristiane Bitencourt Dias; Luis Yu; Viktoria Woronik; Livia Barreira Cavalcante; Denise Maria Avancini Costa Malheiros; Lectícia Barbosa Jorge
Journal:  J Nephrol       Date:  2021-02-11       Impact factor: 3.902

Review 3.  Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?

Authors:  F M Rasche; F Keller; W G Rasche; S Schiekofer; A Boldt; U Sack; J Fahnert
Journal:  Clin Exp Immunol       Date:  2016-09-08       Impact factor: 4.330

Review 4.  Treatment of IgA nephropathy and Henoch-Schönlein nephritis.

Authors:  Jürgen Floege; John Feehally
Journal:  Nat Rev Nephrol       Date:  2013-04-02       Impact factor: 28.314

Review 5.  Thrombotic Microangiopathy and the Kidney.

Authors:  Vicky Brocklebank; Katrina M Wood; David Kavanagh
Journal:  Clin J Am Soc Nephrol       Date:  2017-10-17       Impact factor: 8.237

Review 6.  Current Understanding of the Role of Complement in IgA Nephropathy.

Authors:  Nicolas Maillard; Robert J Wyatt; Bruce A Julian; Krzysztof Kiryluk; Ali Gharavi; Veronique Fremeaux-Bacchi; Jan Novak
Journal:  J Am Soc Nephrol       Date:  2015-02-18       Impact factor: 10.121

Review 7.  Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics.

Authors:  Fadi Fakhouri; Véronique Frémeaux-Bacchi
Journal:  Nat Rev Nephrol       Date:  2021-05-05       Impact factor: 28.314

8.  Deletion Variants of CFHR1 and CFHR3 Associate with Mesangial Immune Deposits but Not with Progression of IgA Nephropathy.

Authors:  Perrine Jullien; Blandine Laurent; Guillaume Claisse; Ingrid Masson; Miriana Dinic; Damien Thibaudin; Francois Berthoux; Eric Alamartine; Christophe Mariat; Nicolas Maillard
Journal:  J Am Soc Nephrol       Date:  2017-11-07       Impact factor: 10.121

9.  Association of C4d deposition with clinical outcomes in IgA nephropathy.

Authors:  Mario Espinosa; Rosa Ortega; Marina Sánchez; Alfons Segarra; Maria Teresa Salcedo; Fayna González; Rafael Camacho; Miguel Angel Valdivia; Rocio Cabrera; Katia López; Fernando Pinedo; Eduardo Gutierrez; Alfonso Valera; Miryam Leon; Maria Angeles Cobo; Rosa Rodriguez; Jose Ballarín; Yolanda Arce; Beatriz García; María Dolores Muñoz; Manuel Praga
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 8.237

10.  Oxford-MEST classification in IgA nephropathy patients: A report from Iran.

Authors:  Hamid Nasri; Mojgan Mortazavi; Ali Ghorbani; Heshmatollah Shahbazian; Soleiman Kheiri; Azar Baradaran; Afsoon Emami-Naieni; Maryam Saffari; Saeed Mardani; Ali Momeni; Yahya Madihi; Milad Baradaran-Ghahfarokhi; Mahmoud Rafieian-Kopaie; Parin Hedayati; Shahzad Baradaran; Mohammadreza Ardalan; Shahram Sajjadieh; Naziheh Assarzadegan; Seyed Mohammad Ahmadi Soleimani; Mohamad Reza Tamadon
Journal:  J Nephropathol       Date:  2012-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.